Montreal, Quebec, December 8, 2022 – CQDM is pleased to announce the funding of a research study carried out at the Research Institute of the McGill University Health Centre (RI-MUHC) in collaboration with Divocco AI, a Montreal-based company focusing on perioperative care improvement using artificial intelligence (AI)-derived medical devices. The funding, totalling $1,057,502, was made possible by a grant of … Read More
CQDM Funds a Project Aiming to Elucidate the Effets of Psilocybin on Neuronal Circuits in Order to Treat Depression
Montreal (Quebec), November 24, 2022 – CQDM is proud to announce the funding of a research project led by Rosemary Bagot, Associate Professor at the Department of Psychology at McGill University. The project will be funded in collaboration with McGill University, Cubed Biotech Inc. (“Cubed Biotech”), as well as McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative and the Irving … Read More
ADRIQ 2022 Award – Warmest congratulations to Steven LaPlante of INRS and NMX Research and Solutions, winners of the Industrial Sectoral Research Group Award (RSRI) presented by CQDM!
Montréal, November 17, 2022 – During the 32nd ADRIQ 2022 Innovation Awards Gala, Steven LaPlante, a researcher at INRS – Armand-Frappier Santé Biotechnologie Research Centre, and NMX Research and Solutions, a Québec contract research firm, received one of the Industrial Sectoral Research Group Awards (RSRI). Presented by CQDM, this recognition aims to highlight the role of collaborative research as a lever … Read More
The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research
MONTREAL, November 2, 2022 ─ The Canadian Cancer Society (CCS), CQDM, the Cole Foundation and Oncopole – pôle cancer du FRQS announced, today, grants of $8,485,132 to finance four research projects in Quebec, as part of the Pediatric Cancer Research Initiative. This funding, which will take place over three years, is part of a unique partnership created to support pediatric cancer … Read More
JOB OFFER – DIRECTOR SCIENTIFIC AFFAIRS
ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading … Read More
JOB OFFER – ADMINISTRATIVE ASSISTANT
ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading … Read More
CQDM nominates John Delaney and Jennifer Hamilton as Scientific Advisory Board members
MONTREAL, August 30, 2022 – CQDM is very pleased to announce the nomination of John Delaney and Jennifer Hamilton as members of the Scientific Advisory Board (SAB). The SAB is a key committee for CQDM as it provides strategic guidance regarding biopharmaceutical innovation and oversees the selection of projects funded by CQDM. John Delaney is an active retiree sitting on … Read More
JOB OFFER – SENIOR DIRECTOR ACCOUNTING AND FINANCE
ABOUT CQDM Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading pharmaceutical organizations, … Read More
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
Montreal, Quebec, July 12, 2022 ─ CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for patients affected by metastatic cancer. This public-private partnership is made possible through a grant of $824,130 from the … Read More
CQDM and SPM Therapeutics fund a study carried out by Professor Boilard at the CHU de Québec-Université Laval to develop a treatment for systemic lupus erythematosus
Montreal (Quebec), June 16th, 2022 – CQDM is proud to announce the funding of a project in collaboration with the centre hospitalier universitaire (CHU) de Québec-Université Laval, SPM Therapeutics, and the Fondation du CHU de Québec. The funding, totalling $103,158, was made possible by a grant of $51,847 from the Ministère de l’Économie et de l’Innovation (MEI) for this project. … Read More
- Page 1 of 2
- 1
- 2
